Acerus Pharma
2486 Dunwin Drive
Mississauga
Ontario
L5L 1J9
Canada
Tel: 416-679-0771
Website: http://www.aceruspharma.com/
154 articles about Acerus Pharma
-
Acerus to Report Q3-2021 Financial Results and Host Investor Call
11/2/2021
Acerus Pharmaceuticals Corporation will announce its third quarter 2021 financial and operating results on Tuesday, November 9, 2021 before the market opens.
-
Acerus Announces Participation in HC Wainwright Conference
8/23/2021
Acerus Pharmaceuticals Corporation today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15 in New York.
-
Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
8/12/2021
Acerus Pharmaceuticals Corporation today announced that it had accepted a Part 36 settlement offer made by Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB.
-
Acerus Reports Fiscal 2021 Second Quarter Financial ResultsRevenue Triples after Buyback of US Rights for NATESTO®
8/10/2021
Acerus Pharmaceuticals Corporation today reported its financial results for the three and six-month period ended June 30, 2021.
-
Acerus to Report Q2-2021 Financial Results and Host Investor Call
8/3/2021
Acerus Pharmaceuticals Corporation will announce its second quarter 2021 financial and operating results on Tuesday, August 10, 2021 before the market opens.
-
Acerus Announces Voting Results for the 2021 Annual Meeting
6/14/2021
Acerus Pharmaceuticals Corporation announced the voting results from its annual meeting of shareholders held on June 14, 2021 in Toronto, Ontario.
-
Acerus Reports First Quarter 2021 Financial Results
5/13/2021
Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2021.
-
Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
5/10/2021
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that it has entered into a three-year agreement with Amneal Pharmaceuticals Inc. (“Amneal”) to co-promote NATESTO in the U.S. Endocrinology segment, leveraging the company’s extensive relationships with Endocrinology healthcare providers. Amneal will promote NATEST
-
Acerus to Report Q1-2021 Financial Results and Host Investor Call
5/6/2021
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its first quarter 2021 financial and operating results on Thursday, May 13, 2021 before the market opens. The company will also host a conference call on Thursday, May 13, 2021 at 10:00 a.m. Eastern Time.
-
Acerus Announces Closing of US$15 Million Secured Loan Facility
4/30/2021
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a US$15 million subordinated secured loan facility (the “ Loan Facility ”), which will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation Capital Inc.
-
Acerus Announces Expansion of NATESTO® Distribution WorldwideMaylen Farma to Market Treatment in 20 Countries across Europe, Central Asia and the Middle East
3/30/2021
Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a speciality pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement granting Maylen Farma (“Maylen”) the exclusive rights to market NATESTO ® in 20 countries across Europe, Central Asia, and the Middle East.
-
Acerus Reports Fourth Quarter and Full Year 2020 Financial Results
3/11/2021
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2020.
-
Acerus to Report 2020 Financial Results and Host Investor Call
3/4/2021
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2020 financial and operating results on Thursday, March 11, 2021 before the market opens.
-
Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement
12/24/2020
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC (“SWK”) related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based
-
Acerus Announces Details of Previously Completed Rights Offering
11/27/2020
Acerus Pharmaceuticals Corporation (“ Acerus ” or the “ Company ”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the “ Rights Offering ”), Acerus issued 526,600,000 common shares of Acerus (“ Common Shares ”) under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,
-
Acerus Announces Waiver of Third Quarter Financial Covenant in Credit Agreement
9/29/2020
Acerus Pharmaceuticals Corporation announced that the Company has received a waiver letter from SWK Funding LLC related to the required Revenue Covenant for the third quarter of fiscal 2020 in its existing credit facility.
-
Acerus Announces Addition of US Commercial Leader
9/14/2020
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Kevin Hickey has joined the Company as Senior Vice President, US Commercial. Mr. Hickey will become a member of Acerus’ Senior Leadership Team. “I am very pleased to announce that Kevin is joining the Company in this important new role as we strengthen our comme
-
Acerus Reports Fiscal 2020 Second Quarter Financial Results
8/11/2020
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Second Quarter Highlig
-
Acerus to Report Second Quarter 2020 Financial Results and Host Investor Conference Call
8/4/2020
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it will issue second quarter 2020 financial and operating results on Tuesday August 11, 2020 before the market opens. The Company will host an investor conference call that same day, August 11, at 10:00 a.m. Eastern Time, to discuss these results. To access the call live, please dial 416-406-0743 or 1-800-898-3989 and use
-
Acerus Announces Resumption of NATESTO® Shipments
7/28/2020
Acerus Announces Resumption of NATESTO ® Shipments Product En Route to United States and Taiwan TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a speciality pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced that production of new batches of NATESTO ® (testosterone nasal gel) is underway and shipments are already in transit to several key ma